Astellas To Jointly Develop And Market FD Drug With Zeria
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Zeria Pharmaceutical, both based in Tokyo, will co-develop and co-market functional dyspepsia agent Z-338/YM443. Based on the agreement, Zeria will obtain marketing approval in Japan, and both companies will co-market the product under the single brand name. Discovered by Zeria, Z-338/YM443 inhibits peripheral acetylcholinesterase activities, resulting in improvement of delayed gastric emptying, a symptom of FD. Astellas also has obtained exclusive development and marketing rights in North America for Z-338/YM443 and a Phase II trial is underway. (Click here for more - Japanese language